Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global leader in the pharmaceutical, medical device, and over-the-counter product industries, primarily focusing on the therapeutic areas of eye health, gastroenterology, and dermatology. The company is dedicated to advancing global health through innovation and efficient healthcare solutions.
With approximately 22,000 employees worldwide, Bausch Health operates in around 100 countries. The company's core business is organized into five segments: Salix Pharmaceuticals, International, Solta Medical, Diversified Products, and Bausch + Lomb, with the Bausch + Lomb segment generating the highest revenue. Bausch Health consistently delivers on its commitments to quality health care outcomes and customer focus.
Recent achievements include significant progress in the development of Amiselimod, a promising new treatment for ulcerative colitis, and the expansion of public drug plan listings for UCERIS® (budesonide) aerosol foam in multiple Canadian provinces. Additionally, Bausch Health has launched an awareness campaign for XIFAXAN®, an FDA-approved medication for reducing the risk of overt hepatic encephalopathy recurrence.
Financially, Bausch Health reported strong performance in the first quarter of 2024, with revenues of $2.15 billion, marking a 11% increase compared to the prior year. The company continues to strengthen its balance sheet while advancing its R&D pipeline and executing commercial strategies for global growth.
Bausch Health remains focused on protecting its intellectual property, as evidenced by recent litigation efforts to defend the XIFAXAN® franchise. The company is also committed to fostering partnerships and collaborations to enhance its product offerings and reach.
For more information, visit www.bauschhealth.com.
Bausch Health Companies (NYSE/TSX: BHC) announced the presentation of eight posters at the Fall Clinical Dermatology Conference from Oct. 21-24, 2021. These posters will showcase analyses of the efficacy and safety of ARAZLO® (tazarotene) Lotion, DUOBRII® (halobetasol propionate and tazarotene) Lotion, and SILIQ® (brodalumab) injection. The presentations include key findings on long-term outcomes, quality of life improvements, and treatment recommendations for onychomycosis. Two educational events focusing on ARAZLO and DUOBRII will also be held during the conference.
Bausch + Lomb announced positive outcomes from the one-year evaluation of its LuxSmart™ lens, designed for continuous vision from distance to intermediate. Since its 2020 European launch, 5,000 cataract patients have been treated with the lens, adopted by 200 surgeons across 18 countries. Evaluation results indicate excellent vision performance with minimal dysphotopsia. The lens is preloaded and suitable for patients with co-morbidities, with up to 30% of patients gaining near vision.
There is a growing global market for presbyopia solutions, with an expected 1.8 billion people affected by 2050.
Bausch Health Companies Inc. (NYSE/TSX: BHC) will announce its third-quarter 2021 financial results on November 2, 2021, at 8:00 a.m. ET. The event will include a conference call for discussion on the results and a business update, accessible via the company's Investor Relations site. The company specializes in pharmaceutical, medical devices, and over-the-counter products focusing on eye health, gastroenterology, and dermatology.
Bausch Health and Novaliq announced statistically significant topline results from the MOJAVE Phase 3 trial of NOV03, a novel eye drop treatment for dry eye disease associated with Meibomian gland dysfunction. The trial met primary endpoints, showing significant improvements in total corneal staining and dryness scores at day 57, p < 0.001. These findings reaffirm the safety and efficacy observed in earlier trials. A New Drug Application to the FDA is anticipated in 2022, potentially marking a significant advancement in treating millions suffering from dry eye disease.
Bausch Health Companies released its annual Environmental, Social and Governance (ESG) Report on Sept. 29, 2021, emphasizing a commitment to sustainability and stakeholder engagement. The report outlines progress in five key areas: Operate with Integrity, Respect the Environment, Advance Global Health, Improve Communities, and Support Employee Growth. Highlights include enhancing Diversity, Equity & Inclusion initiatives, expanding recycling efforts, and product donations during COVID-19. The full report is available on Bausch Health's website.
Bausch Health announced that new Health Economic Outcomes Research (HEOR) data on RELISTOR will be shared at PAINWeek 2021 in Las Vegas from Sept. 7-11, 2021. The research highlights the use of RELISTOR in treating opioid-induced constipation (OIC) in emergency department patients. Three abstracts will be presented, showcasing broad utilization across care settings. RELISTOR, an opioid antagonist, is indicated for OIC in adults, including those with chronic non-cancer pain and advanced illness.
Bausch Health Companies (NYSE/TSX: BHC) announced participation in several upcoming investor conferences. Executives, including Sam Eldessouky and Joseph C. Papa, will represent the company at the J.P. Morgan European High Yield & Leveraged Finance Conference on Sept. 9, 2021, and the Deutsche Bank 29th Annual Leveraged Finance Conference on Oct. 4, 2021. The Morgan Stanley Global Healthcare Conference is scheduled for Sept. 13, 2021. Live webcasts will be accessible on the company's Investor Relations page.
Bausch Health Companies Inc. (NYSE/TSX: BHC) reported second-quarter 2021 revenues of $2.100 billion, a 26% increase year-over-year. However, the company faced a GAAP net loss of $595 million, worsening from $326 million in Q2 2020. Adjusted EBITDA reached $826 million, up 33%. The company announced plans for an IPO of Solta Medical and appointed Thomas J. Appio as CEO of Bausch Pharma. Guidance for 2021 revenue was revised to $8.40 - $8.60 billion, reflecting divestitures and quality issues.
Bausch Health is pursuing an initial public offering (IPO) of its Solta Medical business, aiming to pay down debt and unlock value from this high-growth medical aesthetics segment. Solta, which reported 2020 revenues of $253 million and a 32% CAGR from 2017 to 2020, provides advanced skin rejuvenation technologies. The IPO is anticipated in Q4 2021 or H1 2022, depending on market conditions. Scott A. Hirsch has been appointed CEO of Solta as Bausch Health prepares for this strategic move.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced plans to reduce its debt by $350 million through the redemption of senior notes due Sept. 2, 2021. This redemption will utilize cash on hand and funds generated from operations. The company has redeemed a total of $1 billion in debt in 2021, enhancing its financial position. An irrevocable notice of redemption will be issued, with payments processed via the Depository Trust Company.
FAQ
What is the current stock price of Bausch Health Companies (BHC)?
What is the market cap of Bausch Health Companies (BHC)?
What are the primary areas of focus for Bausch Health?
How many employees does Bausch Health have?
In how many countries does Bausch Health operate?
What is Bausch Health's largest revenue-generating segment?
What recent product development has Bausch Health achieved?
What financial performance did Bausch Health report for Q1 2024?
How is Bausch Health protecting its intellectual property?
Where can I find more information about Bausch Health?
What recent public drug plan listings has Bausch Health achieved in Canada?
Who is the brand ambassador for the XIFAXAN® awareness campaign?
